<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00940108</url>
  </required_header>
  <id_info>
    <org_study_id>CSLCT-CAL-09-60</org_study_id>
    <nct_id>NCT00940108</nct_id>
  </id_info>
  <brief_title>A Clinical Trial of CSL's 2009 H1N1 Influenza Vaccine (CSL425) in Healthy Children</brief_title>
  <official_title>A Phase II, Multicentre, Randomised, Observer-blind Study to Evaluate the Immunogenicity, Safety and Tolerability of CSL's 2009 H1N1 Influenza Vaccine (CSL425) in Healthy Children Aged &gt;= 6 Months to &lt; 9 Years.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seqirus</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seqirus</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether CSL425 is a safe and effective vaccine for
      eliciting an immune response to H1N1 influenza in healthy children.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2009</start_date>
  <completion_date type="Actual">April 2010</completion_date>
  <primary_completion_date type="Actual">October 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Haemagglutination Inhibition (HI) Antibody Titre Seroconversion Rate After the First Vaccination</measure>
    <time_frame>Before and 21 days after the first vaccination</time_frame>
    <description>HI antibody titre seroconversion was defined as participants with a pre-vaccination titre of less than 1:10 achieving a post-vaccination HI antibody titre of 1:40 or more; or participants with a pre-vaccination HI titre of 1:10 or more achieving a four-fold or greater increase in post-vaccination HI titre.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>HI Antibody Titre Seroconversion Rate After the Second Vaccination</measure>
    <time_frame>Before and 21 days after the second vaccination</time_frame>
    <description>HI antibody titre seroconversion was defined as participants with a pre-vaccination titre of less than 1:10 achieving a post-vaccination HI antibody titre of 1:40 or more; or participants with a pre-vaccination HI titre of 1:10 or more achieving a four-fold or greater increase in post-vaccination HI titre.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Fold Increase (GMFI) in the HI Antibody Titre After the First Vaccination</measure>
    <time_frame>Before and 21 days after the first vaccination</time_frame>
    <description>GMFI in HI antibody titre was defined as the geometric mean of the fold increase in the post-vaccination antibody titre over the pre-vaccination antibody titre.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>GMFI in the HI Antibody Titre After the Second Vaccination</measure>
    <time_frame>Before and 21 days after the second vaccination</time_frame>
    <description>GMFI in HI antibody titre was defined as the geometric mean of the fold increase in the post-vaccination antibody titre over the pre-vaccination antibody titre.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Achieving a HI Antibody Titre of 1:40 or More After the First Vaccination</measure>
    <time_frame>21 days after the first vaccination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Achieving a HI Antibody Titre of 1:40 or More After the Second Vaccination</measure>
    <time_frame>21 days after the second vaccination</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency and Intensity of Solicited Adverse Events (AEs) After the First or Second Vaccination</measure>
    <time_frame>During the 7 days after each vaccination</time_frame>
    <description>Solicited AEs included AEs that were specifically sought for. Grade 3 solicited AE definitions: Cried when limb was moved/spontaneously painful (Cohort A) or prevented normal daily activities (Cohort B) for injection site pain; Size &gt; 100 mm for injection site redness and induration/swelling; Temperature &gt; 103.1째F (39.5째C) for fevers; Prevented normal daily activities or required medical intervention for all other systemic AEs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Solicited AEs After the First Vaccination</measure>
    <time_frame>During the 7 days after the first vaccination and up to Day 20 after the first vaccination if AE is ongoing at Day 7.</time_frame>
    <description>Solicited AEs included AEs that were specifically sought for.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Solicited AEs After the Second Vaccination</measure>
    <time_frame>During the 7 days after the second vaccination and up to Day 20 after the second vaccination if AE was ongoing at Day 7.</time_frame>
    <description>Solicited AEs included AEs that were specifically sought for.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Serious Adverse Events (SAEs), Adverse Events of Special Interest (AESIs), and New Onset of Chronic Illnesses (NOCIs)</measure>
    <time_frame>Up to 180 days after the last vaccination</time_frame>
    <description>An AESI was defined as an AE for which the association with seasonal influenza vaccine was unclear. A NOCI was defined as the diagnosis of a new medical condition that was chronic in nature, including those potentially controllable by medication (eg, diabetes, asthma).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency and Intensity of Unsolicited Adverse Events After the First or Second Vaccination</measure>
    <time_frame>During the 21 days after each vaccination; up to 180 days after the last vaccination for SAEs, AESIs, and NOCIs</time_frame>
    <description>Unsolicited AEs included AEs other than those specifically sought for. Grade 1 unsolicited AE definition: Easily tolerated and did not interfere with normal daily activities. Grade 2 unsolicited AE definition: Some interference with normal daily activities. Grade 3 unsolicited AE definition: Prevented normal daily activities.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">370</enrollment>
  <condition>Influenza Caused by the Novel Influenza A (H1N1) Virus</condition>
  <arm_group>
    <arm_group_label>CSL425 (15 mcg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>15 mcg of hemagglutinin antigen per dose. 0.25 mL intramuscular injection into the deltoid region of the arm on Day 0 and Day 21</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CSL425 (30 mcg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>30 mcg of hemagglutinin antigen per dose. 0.5 mL intramuscular injection into the deltoid region of the arm on Day 0 and Day 21</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CSL425</intervention_name>
    <description>CSL's 2009 H1N1 Influenza Vaccine, thimerosal-free</description>
    <arm_group_label>CSL425 (15 mcg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CSL425</intervention_name>
    <description>CSL's 2009 H1N1 Influenza Vaccine, thimerosal-free</description>
    <arm_group_label>CSL425 (30 mcg)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female aged &gt;= 6 months to &lt; 9 years at the time of the first study
             vaccination.

          -  For children &lt; 3 years of age at the time of first vaccination, born at or after 36
             weeks of gestation.

        Exclusion Criteria:

          -  Known hypersensitivity to a previous dose of influenza virus vaccine or allergy to
             eggs, chicken protein, thiomersal, neomycin, polymyxin, or any components of the Study
             Vaccine.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>8 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Director Vaccines</last_name>
    <role>Study Director</role>
    <affiliation>Seqirus</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <zip>4006</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>North Adelaide</city>
        <state>South Australia</state>
        <zip>5006</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Carlton</city>
        <state>Victoria</state>
        <zip>3010</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Subiaco</city>
        <state>Western Australia</state>
        <zip>6027</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <results_reference>
    <citation>Nolan T, McVernon J, Skeljo M, Richmond P, Wadia U, Lambert S, Nissen M, Marshall H, Booy R, Heron L, Hartel G, Lai M, Basser R, Gittleson C, Greenberg M. Immunogenicity of a monovalent 2009 influenza A(H1N1) vaccine in infants and children: a randomized trial. JAMA. 2010 Jan 6;303(1):37-46. doi: 10.1001/jama.2009.1911. Epub 2009 Dec 21.</citation>
    <PMID>20026597</PMID>
  </results_reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 13, 2009</study_first_submitted>
  <study_first_submitted_qc>July 14, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 15, 2009</study_first_posted>
  <results_first_submitted>July 9, 2013</results_first_submitted>
  <results_first_submitted_qc>October 28, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 20, 2013</results_first_posted>
  <last_update_submitted>October 23, 2017</last_update_submitted>
  <last_update_submitted_qc>October 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>One randomized participant withdrew consent prior to vaccine administration and was not included in the participant flow data or in any analysis population.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>CSL425 (15 mcg) Cohort A</title>
          <description>Participants aged 6 months to less than 3 years received two doses of CSL425 (15 mcg of haemagglutinin antigen per 0.25 mL dose) by intramuscular injection into the deltoid region of the arm on Day 0 and Day 21.</description>
        </group>
        <group group_id="P2">
          <title>CSL425 (30 mcg) Cohort A</title>
          <description>Participants aged 6 months to less than 3 years received two doses of CSL425 (30 mcg of haemagglutinin antigen per 0.5 mL dose) by intramuscular injection into the deltoid region of the arm on Day 0 and Day 21.</description>
        </group>
        <group group_id="P3">
          <title>CSL425 (15 mcg) Cohort B</title>
          <description>Participants aged 3 years to less than 9 years received two doses of CSL425 (15 mcg of haemagglutinin antigen per 0.25 mL dose) by intramuscular injection into the deltoid region of the arm on Day 0 and Day 21.</description>
        </group>
        <group group_id="P4">
          <title>CSL425 (30 mcg) Cohort B</title>
          <description>Participants aged 3 years to less than 9 years received two doses of CSL425 (30 mcg of haemagglutinin antigen per 0.5 mL dose) by intramuscular injection into the deltoid region of the arm on Day 0 and Day 21.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="82"/>
                <participants group_id="P2" count="80"/>
                <participants group_id="P3" count="103"/>
                <participants group_id="P4" count="104"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="77"/>
                <participants group_id="P2" count="71"/>
                <participants group_id="P3" count="100"/>
                <participants group_id="P4" count="99"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrew Consent</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Dose 2 contraindicated</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Declined further vaccination</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Refused - pyrexia after Dose 1</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Viral illness after Dose 1</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Diagnosed with H1N1</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>CSL425 (15 mcg) Cohort A</title>
          <description>Participants aged 6 months to less than 3 years received two doses of CSL425 (15 mcg of haemagglutinin antigen per 0.25 mL dose) by intramuscular injection into the deltoid region of the arm on Day 0 and Day 21.</description>
        </group>
        <group group_id="B2">
          <title>CSL425 (30 mcg) Cohort A</title>
          <description>Participants aged 6 months to less than 3 years received two doses of CSL425 (30 mcg of haemagglutinin antigen per 0.5 mL dose) by intramuscular injection into the deltoid region of the arm on Day 0 and Day 21.</description>
        </group>
        <group group_id="B3">
          <title>CSL425 (15 mcg) Cohort B</title>
          <description>Participants aged 3 years to less than 9 years received two doses of CSL425 (15 mcg of haemagglutinin antigen per 0.25 mL dose) by intramuscular injection into the deltoid region of the arm on Day 0 and Day 21.</description>
        </group>
        <group group_id="B4">
          <title>CSL425 (30 mcg) Cohort B</title>
          <description>Participants aged 3 years to less than 9 years received two doses of CSL425 (30 mcg of haemagglutinin antigen per 0.5 mL dose) by intramuscular injection into the deltoid region of the arm on Day 0 and Day 21.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="82"/>
            <count group_id="B2" value="80"/>
            <count group_id="B3" value="103"/>
            <count group_id="B4" value="104"/>
            <count group_id="B5" value="369"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.68" spread="0.67"/>
                    <measurement group_id="B2" value="1.73" spread="0.74"/>
                    <measurement group_id="B3" value="5.78" spread="1.69"/>
                    <measurement group_id="B4" value="5.66" spread="1.74"/>
                    <measurement group_id="B5" value="3.96" spread="2.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="53"/>
                    <measurement group_id="B4" value="49"/>
                    <measurement group_id="B5" value="184"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="50"/>
                    <measurement group_id="B4" value="55"/>
                    <measurement group_id="B5" value="185"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Haemagglutination Inhibition (HI) Antibody Titre Seroconversion Rate After the First Vaccination</title>
        <description>HI antibody titre seroconversion was defined as participants with a pre-vaccination titre of less than 1:10 achieving a post-vaccination HI antibody titre of 1:40 or more; or participants with a pre-vaccination HI titre of 1:10 or more achieving a four-fold or greater increase in post-vaccination HI titre.</description>
        <time_frame>Before and 21 days after the first vaccination</time_frame>
        <population>The Evaluable Population (for the first vaccination) comprised all randomised participants who received the first study vaccination; provided both pre- and post-vaccination blood samples; were not excluded from analyses (eg, for the use of a prohibited medication or a laboratory-confirmed 2009 H1N1 infection between Visit 1 and Visit 3).</population>
        <group_list>
          <group group_id="O1">
            <title>CSL425 (15 mcg) Cohort A</title>
            <description>Participants aged 6 months to less than 3 years received two doses of CSL425 (15 mcg of haemagglutinin antigen per 0.25 mL dose) by intramuscular injection into the deltoid region of the arm on Day 0 and Day 21.</description>
          </group>
          <group group_id="O2">
            <title>CSL425 (30 mcg) Cohort A</title>
            <description>Participants aged 6 months to less than 3 years received two doses of CSL425 (30 mcg of haemagglutinin antigen per 0.5 mL dose) by intramuscular injection into the deltoid region of the arm on Day 0 and Day 21.</description>
          </group>
          <group group_id="O3">
            <title>CSL425 (15 mcg) Cohort B</title>
            <description>Participants aged 3 years to less than 9 years received two doses of CSL425 (15 mcg of haemagglutinin antigen per 0.25 mL dose) by intramuscular injection into the deltoid region of the arm on Day 0 and Day 21.</description>
          </group>
          <group group_id="O4">
            <title>CSL425 (30 mcg) Cohort B</title>
            <description>Participants aged 3 years to less than 9 years received two doses of CSL425 (30 mcg of haemagglutinin antigen per 0.5 mL dose) by intramuscular injection into the deltoid region of the arm on Day 0 and Day 21.</description>
          </group>
        </group_list>
        <measure>
          <title>Haemagglutination Inhibition (HI) Antibody Titre Seroconversion Rate After the First Vaccination</title>
          <description>HI antibody titre seroconversion was defined as participants with a pre-vaccination titre of less than 1:10 achieving a post-vaccination HI antibody titre of 1:40 or more; or participants with a pre-vaccination HI titre of 1:10 or more achieving a four-fold or greater increase in post-vaccination HI titre.</description>
          <population>The Evaluable Population (for the first vaccination) comprised all randomised participants who received the first study vaccination; provided both pre- and post-vaccination blood samples; were not excluded from analyses (eg, for the use of a prohibited medication or a laboratory-confirmed 2009 H1N1 infection between Visit 1 and Visit 3).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="73"/>
                <count group_id="O3" value="98"/>
                <count group_id="O4" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.2" lower_limit="78.7" upper_limit="94.4"/>
                    <measurement group_id="O2" value="97.3" lower_limit="90.5" upper_limit="99.7"/>
                    <measurement group_id="O3" value="85.7" lower_limit="77.2" upper_limit="92.0"/>
                    <measurement group_id="O4" value="91.9" lower_limit="84.7" upper_limit="96.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>HI Antibody Titre Seroconversion Rate After the Second Vaccination</title>
        <description>HI antibody titre seroconversion was defined as participants with a pre-vaccination titre of less than 1:10 achieving a post-vaccination HI antibody titre of 1:40 or more; or participants with a pre-vaccination HI titre of 1:10 or more achieving a four-fold or greater increase in post-vaccination HI titre.</description>
        <time_frame>Before and 21 days after the second vaccination</time_frame>
        <population>The Evaluable Population (for the second vaccination) comprised all randomised participants who received the second study vaccination; provided both pre- and post-vaccination blood samples; were not excluded from analyses (eg, for the use of a prohibited medication or a laboratory-confirmed 2009 H1N1 infection between Visit 1 and Visit 3).</population>
        <group_list>
          <group group_id="O1">
            <title>CSL425 (15 mcg) Cohort A</title>
            <description>Participants aged 6 months to less than 3 years received two doses of CSL425 (15 mcg of haemagglutinin antigen per 0.25 mL dose) by intramuscular injection into the deltoid region of the arm on Day 0 and Day 21.</description>
          </group>
          <group group_id="O2">
            <title>CSL425 (30 mcg) Cohort A</title>
            <description>Participants aged 6 months to less than 3 years received two doses of CSL425 (30 mcg of haemagglutinin antigen per 0.5 mL dose) by intramuscular injection into the deltoid region of the arm on Day 0 and Day 21.</description>
          </group>
          <group group_id="O3">
            <title>CSL425 (15 mcg) Cohort B</title>
            <description>Participants aged 3 years to less than 9 years received two doses of CSL425 (15 mcg of haemagglutinin antigen per 0.25 mL dose) by intramuscular injection into the deltoid region of the arm on Day 0 and Day 21.</description>
          </group>
          <group group_id="O4">
            <title>CSL425 (30 mcg) Cohort B</title>
            <description>Participants aged 3 years to less than 9 years received two doses of CSL425 (30 mcg of haemagglutinin antigen per 0.5 mL dose) by intramuscular injection into the deltoid region of the arm on Day 0 and Day 21.</description>
          </group>
        </group_list>
        <measure>
          <title>HI Antibody Titre Seroconversion Rate After the Second Vaccination</title>
          <description>HI antibody titre seroconversion was defined as participants with a pre-vaccination titre of less than 1:10 achieving a post-vaccination HI antibody titre of 1:40 or more; or participants with a pre-vaccination HI titre of 1:10 or more achieving a four-fold or greater increase in post-vaccination HI titre.</description>
          <population>The Evaluable Population (for the second vaccination) comprised all randomised participants who received the second study vaccination; provided both pre- and post-vaccination blood samples; were not excluded from analyses (eg, for the use of a prohibited medication or a laboratory-confirmed 2009 H1N1 infection between Visit 1 and Visit 3).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="69"/>
                <count group_id="O3" value="95"/>
                <count group_id="O4" value="96"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.9" lower_limit="89.2" upper_limit="99.6"/>
                    <measurement group_id="O2" value="98.6" lower_limit="92.2" upper_limit="100.0"/>
                    <measurement group_id="O3" value="97.9" lower_limit="92.6" upper_limit="99.7"/>
                    <measurement group_id="O4" value="96.9" lower_limit="91.1" upper_limit="99.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Fold Increase (GMFI) in the HI Antibody Titre After the First Vaccination</title>
        <description>GMFI in HI antibody titre was defined as the geometric mean of the fold increase in the post-vaccination antibody titre over the pre-vaccination antibody titre.</description>
        <time_frame>Before and 21 days after the first vaccination</time_frame>
        <population>The Evaluable Population (for the first vaccination) comprised all randomised participants who received the first study vaccination; provided both pre- and post-vaccination blood samples; were not excluded from analyses (eg, for the use of a prohibited medication or a laboratory-confirmed 2009 H1N1 infection between Visit 1 and Visit 3).</population>
        <group_list>
          <group group_id="O1">
            <title>CSL425 (15 mcg) Cohort A</title>
            <description>Participants aged 6 months to less than 3 years received two doses of CSL425 (15 mcg of haemagglutinin antigen per 0.25 mL dose) by intramuscular injection into the deltoid region of the arm on Day 0 and Day 21.</description>
          </group>
          <group group_id="O2">
            <title>CSL425 (30 mcg) Cohort A</title>
            <description>Participants aged 6 months to less than 3 years received two doses of CSL425 (30 mcg of haemagglutinin antigen per 0.5 mL dose) by intramuscular injection into the deltoid region of the arm on Day 0 and Day 21.</description>
          </group>
          <group group_id="O3">
            <title>CSL425 (15 mcg) Cohort B</title>
            <description>Participants aged 3 years to less than 9 years received two doses of CSL425 (15 mcg of haemagglutinin antigen per 0.25 mL dose) by intramuscular injection into the deltoid region of the arm on Day 0 and Day 21.</description>
          </group>
          <group group_id="O4">
            <title>CSL425 (30 mcg) Cohort B</title>
            <description>Participants aged 3 years to less than 9 years received two doses of CSL425 (30 mcg of haemagglutinin antigen per 0.5 mL dose) by intramuscular injection into the deltoid region of the arm on Day 0 and Day 21.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Fold Increase (GMFI) in the HI Antibody Titre After the First Vaccination</title>
          <description>GMFI in HI antibody titre was defined as the geometric mean of the fold increase in the post-vaccination antibody titre over the pre-vaccination antibody titre.</description>
          <population>The Evaluable Population (for the first vaccination) comprised all randomised participants who received the first study vaccination; provided both pre- and post-vaccination blood samples; were not excluded from analyses (eg, for the use of a prohibited medication or a laboratory-confirmed 2009 H1N1 infection between Visit 1 and Visit 3).</population>
          <units>geometric mean fold increase</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="73"/>
                <count group_id="O3" value="98"/>
                <count group_id="O4" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.95" lower_limit="11.39" upper_limit="17.09"/>
                    <measurement group_id="O2" value="22.17" lower_limit="17.87" upper_limit="27.49"/>
                    <measurement group_id="O3" value="13.25" lower_limit="10.84" upper_limit="16.19"/>
                    <measurement group_id="O4" value="15.93" lower_limit="12.87" upper_limit="19.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>GMFI in the HI Antibody Titre After the Second Vaccination</title>
        <description>GMFI in HI antibody titre was defined as the geometric mean of the fold increase in the post-vaccination antibody titre over the pre-vaccination antibody titre.</description>
        <time_frame>Before and 21 days after the second vaccination</time_frame>
        <population>The Evaluable Population (for the second vaccination) comprised all randomised participants who received the second study vaccination; provided both pre- and post-vaccination blood samples; were not excluded from analyses (eg, for the use of a prohibited medication or a laboratory-confirmed 2009 H1N1 infection between Visit 1 and Visit 3).</population>
        <group_list>
          <group group_id="O1">
            <title>CSL425 (15 mcg) Cohort A</title>
            <description>Participants aged 6 months to less than 3 years received two doses of CSL425 (15 mcg of haemagglutinin antigen per 0.25 mL dose) by intramuscular injection into the deltoid region of the arm on Day 0 and Day 21.</description>
          </group>
          <group group_id="O2">
            <title>CSL425 (30 mcg) Cohort A</title>
            <description>Participants aged 6 months to less than 3 years received two doses of CSL425 (30 mcg of haemagglutinin antigen per 0.5 mL dose) by intramuscular injection into the deltoid region of the arm on Day 0 and Day 21.</description>
          </group>
          <group group_id="O3">
            <title>CSL425 (15 mcg) Cohort B</title>
            <description>Participants aged 3 years to less than 9 years received two doses of CSL425 (15 mcg of haemagglutinin antigen per 0.25 mL dose) by intramuscular injection into the deltoid region of the arm on Day 0 and Day 21.</description>
          </group>
          <group group_id="O4">
            <title>CSL425 (30 mcg) Cohort B</title>
            <description>Participants aged 3 years to less than 9 years received two doses of CSL425 (30 mcg of haemagglutinin antigen per 0.5 mL dose) by intramuscular injection into the deltoid region of the arm on Day 0 and Day 21.</description>
          </group>
        </group_list>
        <measure>
          <title>GMFI in the HI Antibody Titre After the Second Vaccination</title>
          <description>GMFI in HI antibody titre was defined as the geometric mean of the fold increase in the post-vaccination antibody titre over the pre-vaccination antibody titre.</description>
          <population>The Evaluable Population (for the second vaccination) comprised all randomised participants who received the second study vaccination; provided both pre- and post-vaccination blood samples; were not excluded from analyses (eg, for the use of a prohibited medication or a laboratory-confirmed 2009 H1N1 infection between Visit 1 and Visit 3).</population>
          <units>geometric mean fold increase</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="69"/>
                <count group_id="O3" value="95"/>
                <count group_id="O4" value="96"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.64" lower_limit="42.87" upper_limit="77.50"/>
                    <measurement group_id="O2" value="72.93" lower_limit="56.10" upper_limit="94.80"/>
                    <measurement group_id="O3" value="37.48" lower_limit="28.33" upper_limit="49.58"/>
                    <measurement group_id="O4" value="37.06" lower_limit="28.77" upper_limit="47.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Achieving a HI Antibody Titre of 1:40 or More After the First Vaccination</title>
        <time_frame>21 days after the first vaccination</time_frame>
        <population>The Evaluable Population (for the first vaccination) comprised all randomised participants who received the first study vaccination; provided both pre- and post-vaccination blood samples; were not excluded from analyses (eg, for the use of a prohibited medication or a laboratory-confirmed 2009 H1N1 infection between Visit 1 and Visit 3).</population>
        <group_list>
          <group group_id="O1">
            <title>CSL425 (15 mcg) Cohort A</title>
            <description>Participants aged 6 months to less than 3 years received two doses of CSL425 (15 mcg of haemagglutinin antigen per 0.25 mL dose) by intramuscular injection into the deltoid region of the arm on Day 0 and Day 21.</description>
          </group>
          <group group_id="O2">
            <title>CSL425 (30 mcg) Cohort A</title>
            <description>Participants aged 6 months to less than 3 years received two doses of CSL425 (30 mcg of haemagglutinin antigen per 0.5 mL dose) by intramuscular injection into the deltoid region of the arm on Day 0 and Day 21.</description>
          </group>
          <group group_id="O3">
            <title>CSL425 (15 mcg) Cohort B</title>
            <description>Participants aged 3 years to less than 9 years received two doses of CSL425 (15 mcg of haemagglutinin antigen per 0.25 mL dose) by intramuscular injection into the deltoid region of the arm on Day 0 and Day 21.</description>
          </group>
          <group group_id="O4">
            <title>CSL425 (30 mcg) Cohort B</title>
            <description>Participants aged 3 years to less than 9 years received two doses of CSL425 (30 mcg of haemagglutinin antigen per 0.5 mL dose) by intramuscular injection into the deltoid region of the arm on Day 0 and Day 21.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving a HI Antibody Titre of 1:40 or More After the First Vaccination</title>
          <population>The Evaluable Population (for the first vaccination) comprised all randomised participants who received the first study vaccination; provided both pre- and post-vaccination blood samples; were not excluded from analyses (eg, for the use of a prohibited medication or a laboratory-confirmed 2009 H1N1 infection between Visit 1 and Visit 3).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="73"/>
                <count group_id="O3" value="98"/>
                <count group_id="O4" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.1" lower_limit="83.6" upper_limit="97.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="95.1" upper_limit="100.0"/>
                    <measurement group_id="O3" value="92.9" lower_limit="85.8" upper_limit="97.1"/>
                    <measurement group_id="O4" value="96.0" lower_limit="90.0" upper_limit="98.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Achieving a HI Antibody Titre of 1:40 or More After the Second Vaccination</title>
        <time_frame>21 days after the second vaccination</time_frame>
        <population>The Evaluable Population (for the second vaccination) comprised all randomised participants who received the second study vaccination; provided both pre- and post-vaccination blood samples; were not excluded from analyses (eg, for the use of a prohibited medication or a laboratory-confirmed 2009 H1N1 infection between Visit 1 and Visit 3).</population>
        <group_list>
          <group group_id="O1">
            <title>CSL425 (15 mcg) Cohort A</title>
            <description>Participants aged 6 months to less than 3 years received two doses of CSL425 (15 mcg of haemagglutinin antigen per 0.25 mL dose) by intramuscular injection into the deltoid region of the arm on Day 0 and Day 21.</description>
          </group>
          <group group_id="O2">
            <title>CSL425 (30 mcg) Cohort A</title>
            <description>Participants aged 6 months to less than 3 years received two doses of CSL425 (30 mcg of haemagglutinin antigen per 0.5 mL dose) by intramuscular injection into the deltoid region of the arm on Day 0 and Day 21.</description>
          </group>
          <group group_id="O3">
            <title>CSL425 (15 mcg) Cohort B</title>
            <description>Participants aged 3 years to less than 9 years received two doses of CSL425 (15 mcg of haemagglutinin antigen per 0.25 mL dose) by intramuscular injection into the deltoid region of the arm on Day 0 and Day 21.</description>
          </group>
          <group group_id="O4">
            <title>CSL425 (30 mcg) Cohort B</title>
            <description>Participants aged 3 years to less than 9 years received two doses of CSL425 (30 mcg of haemagglutinin antigen per 0.5 mL dose) by intramuscular injection into the deltoid region of the arm on Day 0 and Day 21.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving a HI Antibody Titre of 1:40 or More After the Second Vaccination</title>
          <population>The Evaluable Population (for the second vaccination) comprised all randomised participants who received the second study vaccination; provided both pre- and post-vaccination blood samples; were not excluded from analyses (eg, for the use of a prohibited medication or a laboratory-confirmed 2009 H1N1 infection between Visit 1 and Visit 3).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="69"/>
                <count group_id="O3" value="95"/>
                <count group_id="O4" value="96"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="94.4" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="94.8" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="96.2" upper_limit="100.0"/>
                    <measurement group_id="O4" value="100.0" lower_limit="96.2" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency and Intensity of Solicited Adverse Events (AEs) After the First or Second Vaccination</title>
        <description>Solicited AEs included AEs that were specifically sought for. Grade 3 solicited AE definitions: Cried when limb was moved/spontaneously painful (Cohort A) or prevented normal daily activities (Cohort B) for injection site pain; Size &gt; 100 mm for injection site redness and induration/swelling; Temperature &gt; 103.1째F (39.5째C) for fevers; Prevented normal daily activities or required medical intervention for all other systemic AEs.</description>
        <time_frame>During the 7 days after each vaccination</time_frame>
        <population>The Safety Population comprised all participants who received at least one dose of the vaccine and provided follow-up safety data.</population>
        <group_list>
          <group group_id="O1">
            <title>CSL425 (15 mcg) Cohort A</title>
            <description>Participants aged 6 months to less than 3 years received two doses of CSL425 (15 mcg of haemagglutinin antigen per 0.25 mL dose) by intramuscular injection into the deltoid region of the arm on Day 0 and Day 21.</description>
          </group>
          <group group_id="O2">
            <title>CSL425 (30 mcg) Cohort A</title>
            <description>Participants aged 6 months to less than 3 years received two doses of CSL425 (30 mcg of haemagglutinin antigen per 0.5 mL dose) by intramuscular injection into the deltoid region of the arm on Day 0 and Day 21.</description>
          </group>
          <group group_id="O3">
            <title>CSL425 (15 mcg) Cohort B</title>
            <description>Participants aged 3 years to less than 9 years received two doses of CSL425 (15 mcg of haemagglutinin antigen per 0.25 mL dose) by intramuscular injection into the deltoid region of the arm on Day 0 and Day 21.</description>
          </group>
          <group group_id="O4">
            <title>CSL425 (30 mcg) Cohort B</title>
            <description>Participants aged 3 years to less than 9 years received two doses of CSL425 (30 mcg of haemagglutinin antigen per 0.5 mL dose) by intramuscular injection into the deltoid region of the arm on Day 0 and Day 21.</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency and Intensity of Solicited Adverse Events (AEs) After the First or Second Vaccination</title>
          <description>Solicited AEs included AEs that were specifically sought for. Grade 3 solicited AE definitions: Cried when limb was moved/spontaneously painful (Cohort A) or prevented normal daily activities (Cohort B) for injection site pain; Size &gt; 100 mm for injection site redness and induration/swelling; Temperature &gt; 103.1째F (39.5째C) for fevers; Prevented normal daily activities or required medical intervention for all other systemic AEs.</description>
          <population>The Safety Population comprised all participants who received at least one dose of the vaccine and provided follow-up safety data.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
                <count group_id="O2" value="80"/>
                <count group_id="O3" value="103"/>
                <count group_id="O4" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any solicited local AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.5"/>
                    <measurement group_id="O2" value="63.8"/>
                    <measurement group_id="O3" value="68.0"/>
                    <measurement group_id="O4" value="71.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any pain at injection site</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.8"/>
                    <measurement group_id="O2" value="43.8"/>
                    <measurement group_id="O3" value="59.2"/>
                    <measurement group_id="O4" value="64.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 pain at injection site</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2"/>
                    <measurement group_id="O2" value="1.3"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any redness at injection site</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.7"/>
                    <measurement group_id="O2" value="38.8"/>
                    <measurement group_id="O3" value="37.9"/>
                    <measurement group_id="O4" value="37.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 redness at injection site</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1.3"/>
                    <measurement group_id="O3" value="2.9"/>
                    <measurement group_id="O4" value="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any swelling/induration at injection site</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.5"/>
                    <measurement group_id="O2" value="32.5"/>
                    <measurement group_id="O3" value="25.2"/>
                    <measurement group_id="O4" value="26.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 swelling/induration at injection site</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2.5"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any solicited systemic AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.3"/>
                    <measurement group_id="O2" value="93.8"/>
                    <measurement group_id="O3" value="54.4"/>
                    <measurement group_id="O4" value="61.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any nausea/vomiting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.4"/>
                    <measurement group_id="O2" value="30.0"/>
                    <measurement group_id="O3" value="15.5"/>
                    <measurement group_id="O4" value="20.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 nausea/vomiting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2"/>
                    <measurement group_id="O2" value="1.3"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any diarrhoea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.8"/>
                    <measurement group_id="O2" value="32.5"/>
                    <measurement group_id="O3" value="12.6"/>
                    <measurement group_id="O4" value="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 diarrhoea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any loss of appetite</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.2"/>
                    <measurement group_id="O2" value="50.0"/>
                    <measurement group_id="O3" value="NA">Not solicited for in Cohort B</measurement>
                    <measurement group_id="O4" value="NA">Not solicited for in Cohort B</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 loss of appetite</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="NA">Not solicited for in Cohort B</measurement>
                    <measurement group_id="O4" value="NA">Not solicited for in Cohort B</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any irritability</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.4"/>
                    <measurement group_id="O2" value="72.5"/>
                    <measurement group_id="O3" value="NA">Not solicited for in Cohort B</measurement>
                    <measurement group_id="O4" value="NA">Not solicited for in Cohort B</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 irritability</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4"/>
                    <measurement group_id="O2" value="1.3"/>
                    <measurement group_id="O3" value="NA">Not solicited for in Cohort B</measurement>
                    <measurement group_id="O4" value="NA">Not solicited for in Cohort B</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.0"/>
                    <measurement group_id="O2" value="71.3"/>
                    <measurement group_id="O3" value="20.4"/>
                    <measurement group_id="O4" value="29.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2"/>
                    <measurement group_id="O2" value="8.8"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not solicited for in Cohort A</measurement>
                    <measurement group_id="O2" value="NA">Not solicited for in Cohort A</measurement>
                    <measurement group_id="O3" value="27.2"/>
                    <measurement group_id="O4" value="23.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not solicited for in Cohort A</measurement>
                    <measurement group_id="O2" value="NA">Not solicited for in Cohort A</measurement>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any muscle ache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not solicited for in Cohort A</measurement>
                    <measurement group_id="O2" value="NA">Not solicited for in Cohort A</measurement>
                    <measurement group_id="O3" value="15.5"/>
                    <measurement group_id="O4" value="22.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 muscle ache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not solicited for in Cohort A</measurement>
                    <measurement group_id="O2" value="NA">Not solicited for in Cohort A</measurement>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any malaise</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not solicited for in Cohort A</measurement>
                    <measurement group_id="O2" value="NA">Not solicited for in Cohort A</measurement>
                    <measurement group_id="O3" value="19.4"/>
                    <measurement group_id="O4" value="26.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 malaise</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not solicited for in Cohort A</measurement>
                    <measurement group_id="O2" value="NA">Not solicited for in Cohort A</measurement>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Solicited AEs After the First Vaccination</title>
        <description>Solicited AEs included AEs that were specifically sought for.</description>
        <time_frame>During the 7 days after the first vaccination and up to Day 20 after the first vaccination if AE is ongoing at Day 7.</time_frame>
        <population>The Safety Population comprised all participants who received at least one dose of the vaccine and provided follow-up safety data.</population>
        <group_list>
          <group group_id="O1">
            <title>CSL425 (15 mcg) Cohort A</title>
            <description>Participants aged 6 months to less than 3 years received two doses of CSL425 (15 mcg of haemagglutinin antigen per 0.25 mL dose) by intramuscular injection into the deltoid region of the arm on Day 0 and Day 21.</description>
          </group>
          <group group_id="O2">
            <title>CSL425 (30 mcg) Cohort A</title>
            <description>Participants aged 6 months to less than 3 years received two doses of CSL425 (30 mcg of haemagglutinin antigen per 0.5 mL dose) by intramuscular injection into the deltoid region of the arm on Day 0 and Day 21.</description>
          </group>
          <group group_id="O3">
            <title>CSL425 (15 mcg) Cohort B</title>
            <description>Participants aged 3 years to less than 9 years received two doses of CSL425 (15 mcg of haemagglutinin antigen per 0.25 mL dose) by intramuscular injection into the deltoid region of the arm on Day 0 and Day 21.</description>
          </group>
          <group group_id="O4">
            <title>CSL425 (30 mcg) Cohort B</title>
            <description>Participants aged 3 years to less than 9 years received two doses of CSL425 (30 mcg of haemagglutinin antigen per 0.5 mL dose) by intramuscular injection into the deltoid region of the arm on Day 0 and Day 21.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Solicited AEs After the First Vaccination</title>
          <description>Solicited AEs included AEs that were specifically sought for.</description>
          <population>The Safety Population comprised all participants who received at least one dose of the vaccine and provided follow-up safety data.</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
                <count group_id="O2" value="80"/>
                <count group_id="O3" value="103"/>
                <count group_id="O4" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pain at injection site</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.48" spread="0.677"/>
                    <measurement group_id="O2" value="1.52" spread="0.823"/>
                    <measurement group_id="O3" value="1.91" spread="1.221"/>
                    <measurement group_id="O4" value="1.80" spread="1.016"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness at injection site</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.08" spread="1.382"/>
                    <measurement group_id="O2" value="2.23" spread="1.602"/>
                    <measurement group_id="O3" value="2.26" spread="1.347"/>
                    <measurement group_id="O4" value="2.00" spread="1.134"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling/induration at injection site</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.88" spread="0.957"/>
                    <measurement group_id="O2" value="1.64" spread="0.745"/>
                    <measurement group_id="O3" value="1.60" spread="0.737"/>
                    <measurement group_id="O4" value="2.04" spread="1.136"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea/vomiting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.33" spread="0.500"/>
                    <measurement group_id="O2" value="1.05" spread="0.213"/>
                    <measurement group_id="O3" value="1.18" spread="0.405"/>
                    <measurement group_id="O4" value="1.53" spread="1.837"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhoea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.67" spread="1.328"/>
                    <measurement group_id="O2" value="1.55" spread="0.945"/>
                    <measurement group_id="O3" value="1.11" spread="0.333"/>
                    <measurement group_id="O4" value="1.17" spread="0.577"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Loss of appetite</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.32" spread="1.906"/>
                    <measurement group_id="O2" value="1.97" spread="1.447"/>
                    <measurement group_id="O3" value="NA">Not solicited for in Cohort B</measurement>
                    <measurement group_id="O4" value="NA">Not solicited for in Cohort B</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.78" spread="1.560"/>
                    <measurement group_id="O2" value="1.73" spread="1.574"/>
                    <measurement group_id="O3" value="NA">Not solicited for in Cohort B</measurement>
                    <measurement group_id="O4" value="NA">Not solicited for in Cohort B</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.77" spread="1.547"/>
                    <measurement group_id="O2" value="1.52" spread="1.079"/>
                    <measurement group_id="O3" value="1.40" spread="0.737"/>
                    <measurement group_id="O4" value="1.54" spread="1.319"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not solicited for in Cohort A</measurement>
                    <measurement group_id="O2" value="NA">Not solicited for in Cohort A</measurement>
                    <measurement group_id="O3" value="2.04" spread="2.911"/>
                    <measurement group_id="O4" value="1.63" spread="1.149"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Muscle ache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not solicited for in Cohort A</measurement>
                    <measurement group_id="O2" value="NA">Not solicited for in Cohort A</measurement>
                    <measurement group_id="O3" value="1.45" spread="0.688"/>
                    <measurement group_id="O4" value="1.86" spread="2.175"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malaise</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not solicited for in Cohort A</measurement>
                    <measurement group_id="O2" value="NA">Not solicited for in Cohort A</measurement>
                    <measurement group_id="O3" value="1.60" spread="0.910"/>
                    <measurement group_id="O4" value="1.69" spread="1.966"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Solicited AEs After the Second Vaccination</title>
        <description>Solicited AEs included AEs that were specifically sought for.</description>
        <time_frame>During the 7 days after the second vaccination and up to Day 20 after the second vaccination if AE was ongoing at Day 7.</time_frame>
        <population>The Safety Population comprised all participants who received at least one dose of the vaccine and provided follow-up safety data.</population>
        <group_list>
          <group group_id="O1">
            <title>CSL425 (15 mcg) Cohort A</title>
            <description>Participants aged 6 months to less than 3 years received two doses of CSL425 (15 mcg of haemagglutinin antigen per 0.25 mL dose) by intramuscular injection into the deltoid region of the arm on Day 0 and Day 21.</description>
          </group>
          <group group_id="O2">
            <title>CSL425 (30 mcg) Cohort A</title>
            <description>Participants aged 6 months to less than 3 years received two doses of CSL425 (30 mcg of haemagglutinin antigen per 0.5 mL dose) by intramuscular injection into the deltoid region of the arm on Day 0 and Day 21.</description>
          </group>
          <group group_id="O3">
            <title>CSL425 (15 mcg) Cohort B</title>
            <description>Participants aged 3 years to less than 9 years received two doses of CSL425 (15 mcg of haemagglutinin antigen per 0.25 mL dose) by intramuscular injection into the deltoid region of the arm on Day 0 and Day 21.</description>
          </group>
          <group group_id="O4">
            <title>CSL425 (30 mcg) Cohort B</title>
            <description>Participants aged 3 years to less than 9 years received two doses of CSL425 (30 mcg of haemagglutinin antigen per 0.5 mL dose) by intramuscular injection into the deltoid region of the arm on Day 0 and Day 21.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Solicited AEs After the Second Vaccination</title>
          <description>Solicited AEs included AEs that were specifically sought for.</description>
          <population>The Safety Population comprised all participants who received at least one dose of the vaccine and provided follow-up safety data.</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
                <count group_id="O2" value="71"/>
                <count group_id="O3" value="100"/>
                <count group_id="O4" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pain at injection site</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.67" spread="0.966"/>
                    <measurement group_id="O2" value="1.64" spread="1.002"/>
                    <measurement group_id="O3" value="1.90" spread="1.179"/>
                    <measurement group_id="O4" value="1.80" spread="1.040"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness at injection site</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.69" spread="1.004"/>
                    <measurement group_id="O2" value="2.14" spread="1.037"/>
                    <measurement group_id="O3" value="1.92" spread="1.055"/>
                    <measurement group_id="O4" value="1.70" spread="0.822"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling/induration at injection site</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.74" spread="0.872"/>
                    <measurement group_id="O2" value="2.32" spread="1.108"/>
                    <measurement group_id="O3" value="2.24" spread="1.348"/>
                    <measurement group_id="O4" value="2.27" spread="1.751"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea/vomiting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.00" spread="8.832"/>
                    <measurement group_id="O2" value="1.00" spread="0.000"/>
                    <measurement group_id="O3" value="1.43" spread="0.787"/>
                    <measurement group_id="O4" value="1.11" spread="0.333"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhoea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.40" spread="3.777"/>
                    <measurement group_id="O2" value="1.25" spread="0.452"/>
                    <measurement group_id="O3" value="1.40" spread="0.894"/>
                    <measurement group_id="O4" value="2.00" spread="1.000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Loss of appetite</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.15" spread="4.475"/>
                    <measurement group_id="O2" value="1.73" spread="0.883"/>
                    <measurement group_id="O3" value="NA">Not solicited for in Cohort B</measurement>
                    <measurement group_id="O4" value="NA">Not solicited for in Cohort B</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.57" spread="2.410"/>
                    <measurement group_id="O2" value="2.10" spread="1.533"/>
                    <measurement group_id="O3" value="NA">Not solicited for in Cohort B</measurement>
                    <measurement group_id="O4" value="NA">Not solicited for in Cohort B</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.14" spread="3.005"/>
                    <measurement group_id="O2" value="1.63" spread="1.165"/>
                    <measurement group_id="O3" value="1.54" spread="0.877"/>
                    <measurement group_id="O4" value="1.67" spread="1.414"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not solicited for in Cohort A</measurement>
                    <measurement group_id="O2" value="NA">Not solicited for in Cohort A</measurement>
                    <measurement group_id="O3" value="1.33" spread="0.686"/>
                    <measurement group_id="O4" value="1.73" spread="2.412"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Muscle ache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not solicited for in Cohort A</measurement>
                    <measurement group_id="O2" value="NA">Not solicited for in Cohort A</measurement>
                    <measurement group_id="O3" value="1.60" spread="0.516"/>
                    <measurement group_id="O4" value="1.29" spread="0.756"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malaise</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not solicited for in Cohort A</measurement>
                    <measurement group_id="O2" value="NA">Not solicited for in Cohort A</measurement>
                    <measurement group_id="O3" value="1.20" spread="0.422"/>
                    <measurement group_id="O4" value="2.00" spread="1.826"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Serious Adverse Events (SAEs), Adverse Events of Special Interest (AESIs), and New Onset of Chronic Illnesses (NOCIs)</title>
        <description>An AESI was defined as an AE for which the association with seasonal influenza vaccine was unclear. A NOCI was defined as the diagnosis of a new medical condition that was chronic in nature, including those potentially controllable by medication (eg, diabetes, asthma).</description>
        <time_frame>Up to 180 days after the last vaccination</time_frame>
        <population>The Safety Population comprised all participants who received at least one dose of the vaccine and provided follow-up safety data.</population>
        <group_list>
          <group group_id="O1">
            <title>CSL425 (15 mcg) Cohort A</title>
            <description>Participants aged 6 months to less than 3 years received two doses of CSL425 (15 mcg of haemagglutinin antigen per 0.25 mL dose) by intramuscular injection into the deltoid region of the arm on Day 0 and Day 21.</description>
          </group>
          <group group_id="O2">
            <title>CSL425 (30 mcg) Cohort A</title>
            <description>Participants aged 6 months to less than 3 years received two doses of CSL425 (30 mcg of haemagglutinin antigen per 0.5 mL dose) by intramuscular injection into the deltoid region of the arm on Day 0 and Day 21.</description>
          </group>
          <group group_id="O3">
            <title>CSL425 (15 mcg) Cohort B</title>
            <description>Participants aged 3 years to less than 9 years received two doses of CSL425 (15 mcg of haemagglutinin antigen per 0.25 mL dose) by intramuscular injection into the deltoid region of the arm on Day 0 and Day 21.</description>
          </group>
          <group group_id="O4">
            <title>CSL425 (30 mcg) Cohort B</title>
            <description>Participants aged 3 years to less than 9 years received two doses of CSL425 (30 mcg of haemagglutinin antigen per 0.5 mL dose) by intramuscular injection into the deltoid region of the arm on Day 0 and Day 21.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Serious Adverse Events (SAEs), Adverse Events of Special Interest (AESIs), and New Onset of Chronic Illnesses (NOCIs)</title>
          <description>An AESI was defined as an AE for which the association with seasonal influenza vaccine was unclear. A NOCI was defined as the diagnosis of a new medical condition that was chronic in nature, including those potentially controllable by medication (eg, diabetes, asthma).</description>
          <population>The Safety Population comprised all participants who received at least one dose of the vaccine and provided follow-up safety data.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
                <count group_id="O2" value="80"/>
                <count group_id="O3" value="103"/>
                <count group_id="O4" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>At least one SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.9"/>
                    <measurement group_id="O2" value="1.3"/>
                    <measurement group_id="O3" value="1.0"/>
                    <measurement group_id="O4" value="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At least one AESI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4"/>
                    <measurement group_id="O2" value="1.3"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related AESI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At least one NOCI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2"/>
                    <measurement group_id="O2" value="3.8"/>
                    <measurement group_id="O3" value="1.9"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related NOCI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency and Intensity of Unsolicited Adverse Events After the First or Second Vaccination</title>
        <description>Unsolicited AEs included AEs other than those specifically sought for. Grade 1 unsolicited AE definition: Easily tolerated and did not interfere with normal daily activities. Grade 2 unsolicited AE definition: Some interference with normal daily activities. Grade 3 unsolicited AE definition: Prevented normal daily activities.</description>
        <time_frame>During the 21 days after each vaccination; up to 180 days after the last vaccination for SAEs, AESIs, and NOCIs</time_frame>
        <population>The Safety Population comprised all participants who received at least one dose of the vaccine and provided follow-up safety data.</population>
        <group_list>
          <group group_id="O1">
            <title>CSL425 (15 mcg) Cohort A</title>
            <description>Participants aged 6 months to less than 3 years received two doses of CSL425 (15 mcg of haemagglutinin antigen per 0.25 mL dose) by intramuscular injection into the deltoid region of the arm on Day 0 and Day 21.</description>
          </group>
          <group group_id="O2">
            <title>CSL425 (30 mcg) Cohort A</title>
            <description>Participants aged 6 months to less than 3 years received two doses of CSL425 (30 mcg of haemagglutinin antigen per 0.5 mL dose) by intramuscular injection into the deltoid region of the arm on Day 0 and Day 21.</description>
          </group>
          <group group_id="O3">
            <title>CSL425 (15 mcg) Cohort B</title>
            <description>Participants aged 3 years to less than 9 years received two doses of CSL425 (15 mcg of haemagglutinin antigen per 0.25 mL dose) by intramuscular injection into the deltoid region of the arm on Day 0 and Day 21.</description>
          </group>
          <group group_id="O4">
            <title>CSL425 (30 mcg) Cohort B</title>
            <description>Participants aged 3 years to less than 9 years received two doses of CSL425 (30 mcg of haemagglutinin antigen per 0.5 mL dose) by intramuscular injection into the deltoid region of the arm on Day 0 and Day 21.</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency and Intensity of Unsolicited Adverse Events After the First or Second Vaccination</title>
          <description>Unsolicited AEs included AEs other than those specifically sought for. Grade 1 unsolicited AE definition: Easily tolerated and did not interfere with normal daily activities. Grade 2 unsolicited AE definition: Some interference with normal daily activities. Grade 3 unsolicited AE definition: Prevented normal daily activities.</description>
          <population>The Safety Population comprised all participants who received at least one dose of the vaccine and provided follow-up safety data.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
                <count group_id="O2" value="80"/>
                <count group_id="O3" value="103"/>
                <count group_id="O4" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>At least one unsolicited AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.0"/>
                    <measurement group_id="O2" value="82.5"/>
                    <measurement group_id="O3" value="67.0"/>
                    <measurement group_id="O4" value="76.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 1 unsolicited AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.8"/>
                    <measurement group_id="O2" value="33.8"/>
                    <measurement group_id="O3" value="27.2"/>
                    <measurement group_id="O4" value="37.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 2 unsolicited AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.5"/>
                    <measurement group_id="O2" value="41.3"/>
                    <measurement group_id="O3" value="37.9"/>
                    <measurement group_id="O4" value="26.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 unsolicited AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.8"/>
                    <measurement group_id="O2" value="7.5"/>
                    <measurement group_id="O3" value="1.9"/>
                    <measurement group_id="O4" value="11.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>For SAEs: up to 180 days after the last vaccination. For Other AEs: solicited AEs: during the 7 days after each vaccination; unsolicited AEs: during the 21 days after each vaccination; up to 180 days after the last vaccination for AESIs and NOCIs.</time_frame>
      <desc>Unsolicited AEs presented in the organ system &quot;General disorders&quot; with a footnote of &quot;MedDRA V13.0&quot;, were collected under the MedDRA System Organ Class (SOC) 'General disorders and administration site conditions'. Solicited AEs are presented in the organ system &quot;General disorders&quot; and were not collected under the MedDRA SOC.</desc>
      <group_list>
        <group group_id="E1">
          <title>CSL425 (15 mcg) Cohort A</title>
          <description>Participants aged 6 months to less than 3 years received two doses of CSL425 (15 mcg of haemagglutinin antigen per 0.25 mL dose) by intramuscular injection into the deltoid region of the arm on Day 0 and Day 21.</description>
        </group>
        <group group_id="E2">
          <title>CSL425 (30 mcg) Cohort A</title>
          <description>Participants aged 6 months to less than 3 years received two doses of CSL425 (30 mcg of haemagglutinin antigen per 0.5 mL dose) by intramuscular injection into the deltoid region of the arm on Day 0 and Day 21.</description>
        </group>
        <group group_id="E3">
          <title>CSL425 (15 mcg) Cohort B</title>
          <description>Participants aged 3 years to less than 9 years received two doses of CSL425 (15 mcg of haemagglutinin antigen per 0.25 mL dose) by intramuscular injection into the deltoid region of the arm on Day 0 and Day 21.</description>
        </group>
        <group group_id="E4">
          <title>CSL425 (30 mcg) Cohort B</title>
          <description>Participants aged 3 years to less than 9 years received two doses of CSL425 (30 mcg of haemagglutinin antigen per 0.5 mL dose) by intramuscular injection into the deltoid region of the arm on Day 0 and Day 21.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA V13.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Kawasaki's disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA V13.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="81" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="78" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="91" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="96" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="103"/>
                <counts group_id="E4" events="5" subjects_affected="4" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="103"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="82"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="80"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="103"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Teething</sub_title>
                <counts group_id="E1" events="18" subjects_affected="14" subjects_at_risk="82"/>
                <counts group_id="E2" events="19" subjects_affected="12" subjects_at_risk="80"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="80"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="103"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Influenza-like illness</sub_title>
                <counts group_id="E1" events="14" subjects_affected="12" subjects_at_risk="82"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="80"/>
                <counts group_id="E3" events="8" subjects_affected="7" subjects_at_risk="103"/>
                <counts group_id="E4" events="9" subjects_affected="9" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="82"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="80"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="103"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="103"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Pain at Injection Site</sub_title>
                <counts group_id="E1" events="52" subjects_affected="40" subjects_at_risk="82"/>
                <counts group_id="E2" events="47" subjects_affected="35" subjects_at_risk="80"/>
                <counts group_id="E3" events="96" subjects_affected="61" subjects_at_risk="103"/>
                <counts group_id="E4" events="105" subjects_affected="67" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Redness at Injection Site</sub_title>
                <counts group_id="E1" events="66" subjects_affected="44" subjects_at_risk="82"/>
                <counts group_id="E2" events="44" subjects_affected="31" subjects_at_risk="80"/>
                <counts group_id="E3" events="53" subjects_affected="39" subjects_at_risk="103"/>
                <counts group_id="E4" events="52" subjects_affected="39" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Swelling/Induration at Injection Site</sub_title>
                <counts group_id="E1" events="35" subjects_affected="25" subjects_at_risk="82"/>
                <counts group_id="E2" events="33" subjects_affected="26" subjects_at_risk="80"/>
                <counts group_id="E3" events="32" subjects_affected="26" subjects_at_risk="103"/>
                <counts group_id="E4" events="40" subjects_affected="28" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Nausea/Vomiting</sub_title>
                <counts group_id="E1" events="15" subjects_affected="11" subjects_at_risk="82"/>
                <counts group_id="E2" events="26" subjects_affected="24" subjects_at_risk="80"/>
                <counts group_id="E3" events="18" subjects_affected="16" subjects_at_risk="103"/>
                <counts group_id="E4" events="28" subjects_affected="21" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="28" subjects_affected="22" subjects_at_risk="82"/>
                <counts group_id="E2" events="32" subjects_affected="26" subjects_at_risk="80"/>
                <counts group_id="E3" events="14" subjects_affected="13" subjects_at_risk="103"/>
                <counts group_id="E4" events="15" subjects_affected="13" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Loss of Appetite</sub_title>
                <description>Not solicited for in Cohort B.</description>
                <counts group_id="E1" events="48" subjects_affected="33" subjects_at_risk="82"/>
                <counts group_id="E2" events="55" subjects_affected="40" subjects_at_risk="80"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <description>Not solicited for in Cohort B.</description>
                <counts group_id="E1" events="92" subjects_affected="52" subjects_at_risk="82"/>
                <counts group_id="E2" events="99" subjects_affected="58" subjects_at_risk="80"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="51" subjects_affected="41" subjects_at_risk="82"/>
                <counts group_id="E2" events="75" subjects_affected="57" subjects_at_risk="80"/>
                <counts group_id="E3" events="28" subjects_affected="21" subjects_at_risk="103"/>
                <counts group_id="E4" events="37" subjects_affected="31" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <description>Not solicited for in Cohort A.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="42" subjects_affected="28" subjects_at_risk="103"/>
                <counts group_id="E4" events="38" subjects_affected="24" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Muscle Ache (Myalgia)</sub_title>
                <description>Not solicited for in Cohort A.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="21" subjects_affected="16" subjects_at_risk="103"/>
                <counts group_id="E4" events="28" subjects_affected="23" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <description>Not solicited for in Cohort A.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="25" subjects_affected="20" subjects_at_risk="103"/>
                <counts group_id="E4" events="39" subjects_affected="28" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Seasonal allergy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="103"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="28" subjects_affected="22" subjects_at_risk="82"/>
                <counts group_id="E2" events="31" subjects_affected="28" subjects_at_risk="80"/>
                <counts group_id="E3" events="26" subjects_affected="22" subjects_at_risk="103"/>
                <counts group_id="E4" events="26" subjects_affected="24" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="103"/>
                <counts group_id="E4" events="9" subjects_affected="9" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Croup infectious</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="82"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="103"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="103"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="82"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="103"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Hand-foot-and-mouth disease</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="82"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="80"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="82"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="80"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="82"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="80"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="103"/>
                <counts group_id="E4" events="7" subjects_affected="7" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Excoriation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="82"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="103"/>
                <counts group_id="E4" events="8" subjects_affected="6" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E4" events="5" subjects_affected="4" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Accident</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E4" events="4" subjects_affected="3" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="80"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" events="5" subjects_affected="4" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="103"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="103"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="80"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="82"/>
                <counts group_id="E2" events="12" subjects_affected="11" subjects_at_risk="80"/>
                <counts group_id="E3" events="13" subjects_affected="13" subjects_at_risk="103"/>
                <counts group_id="E4" events="12" subjects_affected="11" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Rhinorrhea</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="82"/>
                <counts group_id="E2" events="17" subjects_affected="17" subjects_at_risk="80"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="103"/>
                <counts group_id="E4" events="10" subjects_affected="8" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" events="6" subjects_affected="4" subjects_at_risk="103"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="82"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="80"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="103"/>
                <counts group_id="E4" events="4" subjects_affected="3" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="80"/>
                <counts group_id="E3" events="4" subjects_affected="2" subjects_at_risk="103"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="82"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="80"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Dermatitis diaper</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="82"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>CSL agreements and restrictions on publishing may vary with individual investigators; however, CSL will not prohibit any investigator from publishing. CSL supports the publication of results from all centers of a multi-center trial and generally requires that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Study Disclosure Manager</name_or_title>
      <organization>Seqirus</organization>
      <email>Seqirus.ClinicalTrials@Seqirus.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

